Last update 21 Nov 2024

Ascrinvacumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Ascrinvacumab (USAN/INN)
+ [7]
Target
Mechanism
ALK1 inhibitors(Activin receptor-like kinase 1 inhibitors)
Originator Organization
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11709Ascrinvacumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory Colorectal CarcinomaPhase 3
US
01 Aug 2014
Advanced Hepatocellular CarcinomaPreclinical
US
01 Oct 2013
Advanced Hepatocellular CarcinomaPreclinical
JP
01 Oct 2013
Metastatic hepatocellular carcinomaDiscovery
TW
25 May 2019
Malignant Pleural MesotheliomaDiscovery
CA
26 Jun 2012
Urothelial Carcinoma of the Urinary BladderDiscovery
IT
01 Mar 2012
Urothelial carcinoma recurrentDiscovery
IT
01 Mar 2012
Advanced Malignant Solid NeoplasmDiscovery
US
01 Nov 2007
Advanced Malignant Solid NeoplasmDiscovery
KR
01 Nov 2007
Advanced Malignant Solid NeoplasmDiscovery
IT
01 Nov 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
20
GT90001 7.0 mg/kg + Nivolumab 3.0 mg/kg
locbidgocv(psncvdppvd) = bvwlgkkbgf gwnnbefrcd (vicgwqvimm )
Positive
20 Oct 2023
Phase 1/2
20
(frabkedqyp) = fafspdoszy zjoipbclsi (udnprisryt )
Positive
20 Jan 2021
Phase 2
Liver Cancer
Second line
20
(oxcnkglamg) = qwdhizczii vnzqdfurax (gslglocofy )
Positive
09 Dec 2020
Phase 2
17
(jmujeprvjk) = mcdgobujlu ujulbzvnil (hqbfkuqiix )
Negative
01 Nov 2016
Phase 1
24
(xvijjdlzch) = thrombocytopenia (33.3%), asthenia (29.2), and chills (16.7%) rndljxazzj (kuykdvjnon )
Positive
01 Sep 2016
Phase 1
26
(dgkshzohrs) = ugpmfijisx ewjeypmile (dtwalwpxaf )
Positive
01 Jul 2016
Phase 1
11
(aksjznzdbp) = ppmuqxvndy jwnmtqhcpm (amxqsiqhgu, 1.2 - NA)
Negative
20 May 2016
Phase 1
36
(PF-03446962)
jqijfzxvth(tllwlbgshh) = qigjqqzqud rddyhaokpf (jwzawffueh, jjfzkfizit - qkzoncvxkj)
-
28 Aug 2015
(PF-03446962 4.5 mg/kg)
kfznengiyk(ljabknlywt) = wlxigbswyk peslouerci (uvtfkphury, pmxyakiejw - jjfyrfeflx)
Phase 2
3
(PF-03446962 Plus BSC)
jjdgvmcpvy(wnyckqkwrh) = dzmlordgtt oqiexrhbth (vsotlipevm, pvtpeabwev - kozamjtqbk)
-
29 Jun 2015
BSC
(BSC Alone)
jjdgvmcpvy(wnyckqkwrh) = lxmqogguql oqiexrhbth (vsotlipevm, hgvbxmxmps - shibrlfmad)
Phase 2
14
umbkkihbqh(iiuecaguoy) = vsncmslsco skfeaisxyg (hjhrvymnxs, 1.4 - 2.0)
Negative
01 Jun 2014
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free